 [1m([0morchestrator-hospitalization-BACTRIM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes BACTRIM increase or decrease the risk of hospitalization?[0m
 [1m([0morchestrator-hospitalization-BACTRIM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-BACTRIM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hospitalization-BACTRIM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does BACTRIM increase or decrease the risk of hospitalization?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hospitalization-BACTRIM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes BACTRIM increase or decrease the risk of hospitalization?[0m
 [1m([0morchestrator-hospitalization-BACTRIM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-BACTRIM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hospitalization-BACTRIM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes BACTRIM increase or decrease the risk of hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does BACTRIM increase or decrease the risk of hospitalization?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"BACTRIM"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: BACTRIM: geriatric_use: Geriatric Use Clinical studies of BACTRIM did not include sufficient numbers of subjects aged [0m[1;31m65[0m[31m and over to determine whether they respond differently from younger [0m
[31msubjects. There may be an increased risk of severe adverse reactions in elderly patients, particularly when complicating conditions exist, e.g., impaired kidney and/or liver function, possible folate [0m
[31mdeficiency, or concomitant use of other drugs. Severe skin reactions, generalized bone marrow suppression [0m[1;31m([0m[31msee WARNINGS and ADVERSE REACTIONS sections[0m[1;31m)[0m[31m, a specific decrease in platelets [0m[1;31m([0m[31mwith or [0m
[31mwithout purpura[0m[1;31m)[0m[31m, and hyperkalemia are the most frequently reported severe adverse reactions in elderly patients. In those concurrently receiving certain diuretics, primarily thiazides, an increased [0m
[31mincidence of thrombocytopenia with purpura has been reported. Increased digoxin blood levels can occur with concomitant BACTRIM therapy, especially in elderly patients. Serum digoxin levels should be [0m
[31mmonitored. BACTRIM: geriatric_use: Hematological changes indicative of folic acid deficiency may occur in elderly patients. These effects are reversible by folinic acid therapy. Appropriate dosage [0m
[31madjustments should be made for patients with impaired kidney function and duration of use should be as short as possible to minimize risks of undesired reactions [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m
[31msection[0m[1;31m)[0m[31m. The trimethoprim component of BACTRIM may cause hyperkalemia when administered to patients with underlying disorders of potassium metabolism, with renal insufficiency or when given [0m
[31mconcomitantly with drugs known to induce hyperkalemia, such as angiotensin converting enzyme inhibitors. Close monitoring of serum potassium is warranted in these patients. Discontinuation of BACTRIM [0m
[31mtreatment is recommended to help lower potassium serum levels. Bactrim Tablets contain [0m[1;31m1.8[0m[31m mg sodium [0m[1;31m([0m[1;31m0.08[0m[31m mEq[0m[1;31m)[0m[31m of sodium per tablet. Bactrim DS Tablets contain [0m[1;31m3.6[0m[31m mg [0m[1;31m([0m[1;31m0.16[0m[31m mEq[0m[1;31m)[0m[31m of sodium per tablet.[0m
[31mBACTRIM: geriatric_use: Pharmacokinetics parameters for sulfamethoxazole were similar for geriatric subjects and younger adult subjects. The mean maximum serum trimethoprim concentration was higher [0m
[31mand mean renal clearance of trimethoprim was lower in geriatric subjects compared with younger subjects [0m[1;31m([0m[31msee CLINICAL PHARMACOLOGY: Geriatric Pharmacokinetics [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m


[31mCONTENT: BACTRIM: drug_interactions_table: paragraph>[0m[1;31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Indomethacin<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule [0m
[31mBotrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Avoid concurrent use<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Increased sulfamethoxazole blood levels may occur in patients who [0m
[31mare also receiving indomethacin. BACTRIM: drug_interactions_table: paragraph><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Pyrimethamine<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m
[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Avoid concurrent use<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Occasional reports suggest that patients [0m
[31mreceiving pyrimethamine as malaria prophylaxis in doses exceeding [0m[1;31m25[0m[31m mg weekly may develop megaloblastic anemia if BACTRIM is prescribed. BACTRIM: drug_interactions_table: paragraph><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m
[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Tricyclic<[0m[31m/[0m[31mparagraph[0m[31m><paragraph>Antidepressants<[0m[31m/[0m[31mparagraph[0m[31m><paragraph>[0m[1;31m([0m[31mTCAs[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule [0m
[31m"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Monitor therapeutic response and adjust dose of TCA accordingly<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>The efficacy of tricyclic [0m
[31mantidepressants can decrease when coadministered with BACTRIM. BACTRIM: drug_interactions_table: paragraph><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Oral [0m
[31mHypoglycemics<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Monitor blood glucose more frequently<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Like other sulfonamide-containing drugs, BACTRIM potentiates the effect of oral hypoglycemic that are metabolized by CYP2C8 [0m[1;31m([0m[31me.g., pioglitazone, repaglinide, and rosiglitazone[0m[1;31m)[0m
[31mor CYP2C9 [0m[1;31m([0m[31me.g., glipizide and glyburide[0m[1;31m)[0m[31m or eliminated renally via OCT2 [0m[1;31m([0m[31me.g., metformin[0m[1;31m)[0m[31m. Additional monitoring of blood glucose may be warranted. BACTRIM: drug_interactions_table: [0m
[31mparagraph><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Amantadine<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Avoid [0m
[31mconcurrent use<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph[0m[1;31m>[0m[31mIn the literature, a single case of toxic delirium has been reported after concomitant intake of BACTRIM and[0m
[31mamantadine [0m[1;31m([0m[31man OCT2 substrate[0m[1;31m)[0m[31m. Cases of interactions with other OCT2 substrates, memantine and metformin, have also been reported.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m


[31mCONTENT: BACTRIM: precautions: Potential Risk in the Treatment of Pneumocystis jirovecii Pneumonia in Patients with Acquired Immunodeficiency Syndrome [0m[1;31m([0m[31mAIDS[0m[1;31m)[0m[31m AIDS patients may not tolerate or respond [0m
[31mto BACTRIM in the same manner as non-AIDS patients. The incidence of adverse reactions, particularly rash, fever, leukopenia and elevated aminotransferase [0m[1;31m([0m[31mtransaminase[0m[1;31m)[0m[31m values, with BACTRIM therapy [0m
[31min AIDS patients who are being treated for P. jirovecii pneumonia has been reported to be increased compared with the incidence normally associated with the use of BACTRIM in non-AIDS patients. If a [0m
[31mpatient develops skin rash, fever, leukopenia or any sign of adverse reaction, reevaluate benefit-risk of continuing therapy or re-challenge with BACTRIM [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Avoid coadministration of [0m
[31mBACTRIM and leucovorin during treatment of P. jirovecii pneumonia [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. BACTRIM: precautions: Electrolyte Abnormalities Hyperkalemia : High dosage of trimethoprim, as used in patients with [0m
[31mP. jirovecii pneumonia, induces a progressive but reversible increase of serum potassium concentrations in a substantial number of patients. Even treatment with recommended doses may cause [0m
[31mhyperkalemia when trimethoprim is administered to patients with underlying disorders of potassium metabolism, with renal insufficiency, or if drugs known to induce hyperkalemia are given [0m
[31mconcomitantly. Close monitoring of serum potassium is warranted in these patients. Hyponatremia : Severe and symptomatic hyponatremia can occur in patients receiving BACTRIM, particularly for the [0m
[31mtreatment of P. jirovecii pneumonia. Evaluation for hyponatremia and appropriate correction is necessary in symptomatic patients to prevent life-threatening complications. Crystalluria : During [0m
[31mtreatment, ensure adequate fluid intake and urinary output to prevent crystalluria. BACTRIM: precautions: Patients who are â€œslow acetylatorsâ€ may be more prone to idiosyncratic reactions to [0m
[31msulfonamides. Information for Patients Patients should be counseled that antibacterial drugs including Bactrim [0m[1;31m([0m[31msulfamethoxazole and trimethoprim[0m[1;31m)[0m[31m tablets should only be used to treat bacterial [0m
[31minfections. They do not treat viral infections [0m[1;31m([0m[31me.g., the common cold[0m[1;31m)[0m[31m. When Bactrim [0m[1;31m([0m[31msulfamethoxazole and trimethoprim[0m[1;31m)[0m[31m tablets are prescribed to treat a bacterial infection, patients should be told [0m
[31mthat although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m [0m
[31mdecrease the effectiveness of the immediate treatment and [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m increase the likelihood that bacteria will develop resistance and will not be treatable by Bactrim [0m[1;31m([0m[31msulfamethoxazole and trimethoprim[0m[1;31m)[0m[31m [0m
[31mtablets or other antibacterial drugs in the future. BACTRIM: precautions: Patients should be instructed to maintain an adequate fluid intake in order to prevent crystalluria and stone formation. [0m
[31mDiarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody [0m
[31mstools [0m[1;31m([0m[31mwith or without stomach cramps and fever[0m[1;31m)[0m[31m even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon[0m
[31mas possible. Laboratory Tests Complete blood counts and clinical chemistry testing should be done frequently in patients receiving BACTRIM. Perform urinalyses with careful microscopic examination and [0m
[31mrenal function tests during therapy, particularly for those patients with impaired renal function. Discontinue BACTRIM if a significant electrolyte abnormality, renal insufficiency or reduction in the[0m
[31mcount of any formed blood element is noted. BACTRIM: drug_interactions: Drug Interactions Potential for BACTRIM to Affect Other Drugs Trimethoprim is an inhibitor of CYP2C8 as well as OCT2 [0m
[31mtransporter. Sulfamethoxazole is an inhibitor of CYP2C9. Avoid coadministration of BACTRIM with drugs that are substrates of CYP2C8 and 2C9 or OCT2. Table [0m[1;31m1[0m[31m: Drug Interactions with BACTRIM [0m[1;31mDrug[0m[1;31m([0m[31ms[0m[1;31m)[0m[31m [0m
[31mRecommendation Comments Diuretics Avoid concurrent use In elderly patients concurrently receiving certain diuretics, primarily thiazides, an increased incidence of thrombocytopenia with purpura has [0m
[31mbeen reported. Warfarin Monitor prothrombin time and INR It has been reported that BACTRIM may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin [0m[1;31m([0m[31ma CYP2C9 [0m
[31msubstrate[0m[1;31m)[0m[31m. BACTRIM: drug_interactions: This interaction should be kept in mind when BACTRIM is given to patients already on anticoagulant therapy, and the coagulation time should be reassessed. [0m
[31mPhenytoin Monitor serum phenytoin levels BACTRIM may inhibit the hepatic metabolism of phenytoin [0m[1;31m([0m[31ma CYP2C9 substrate[0m[1;31m)[0m[31m. BACTRIM, given at a common clinical dosage, increased the phenytoin half-life by [0m
[1;31m39[0m[31m% and decreased the phenytoin metabolic clearance rate by [0m[1;31m27[0m[31m%. When administering these drugs concurrently, one should be alert for possible excessive phenytoin effect. Methotrexate Avoid concurrent[0m
[31muse Sulfonamides can also displace methotrexate from plasma protein binding sites and can compete with the renal transport of methotrexate, thus increasing free methotrexate concentrations.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m


[31mCONTENT: BACTRIM: information_for_patients: Information for Patients Patients should be counseled that antibacterial drugs including Bactrim [0m[1;31m([0m[31msulfamethoxazole and trimethoprim[0m[1;31m)[0m[31m tablets should only be [0m
[31mused to treat bacterial infections. They do not treat viral infections [0m[1;31m([0m[31me.g., the common cold[0m[1;31m)[0m[31m. When Bactrim [0m[1;31m([0m[31msulfamethoxazole and trimethoprim[0m[1;31m)[0m[31m tablets are prescribed to treat a bacterial infection, [0m
[31mpatients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course [0m
[31mof therapy may [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m decrease the effectiveness of the immediate treatment and [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m increase the likelihood that bacteria will develop resistance and will not be treatable by Bactrim [0m[1;31m([0m[31msulfamethoxazole [0m
[31mand trimethoprim[0m[1;31m)[0m[31m tablets or other antibacterial drugs in the future. Patients should be instructed to maintain an adequate fluid intake in order to prevent crystalluria and stone formation. BACTRIM: [0m
[31minformation_for_patients: Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can [0m
[31mdevelop watery and bloody stools [0m[1;31m([0m[31mwith or without stomach cramps and fever[0m[1;31m)[0m[31m even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should [0m
[31mcontact their physician as soon as possible.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m


[31mCONTENT: BACTRIM: laboratory_tests: Laboratory Tests Complete blood counts and clinical chemistry testing should be done frequently in patients receiving BACTRIM. Perform urinalyses with careful [0m
[31mmicroscopic examination and renal function tests during therapy, particularly for those patients with impaired renal function. Discontinue BACTRIM if a significant electrolyte abnormality, renal [0m
[31minsufficiency or reduction in the count of any formed blood element is noted.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m


[31mCONTENT: BACTRIM: teratogenic_effects: Teratogenic Effects Human Data While there are no large prospective, well controlled studies in pregnant women and their babies, some retrospective epidemiologic[0m
[31mstudies suggest an association between first trimester exposure to sulfamethoxazole and trimethoprim with an increased risk of congenital malformations, particularly neural tube defects, [0m
[31mcardiovascular abnormalities, urinary tract defects, oral clefts, and club foot. These studies, however, were limited by the small number of exposed cases and the lack of adjustment for multiple [0m
[31mstatistical comparisons and confounders. These studies are further limited by recall, selection, and information biases, and by limited generalizability of their findings. Lastly, outcome measures [0m
[31mvaried between studies, limiting cross-study comparisons. Alternatively, other epidemiologic studies did not detect statistically significant associations between sulfamethoxazole and trimethoprim [0m
[31mexposure and specific malformations. BACTRIM: precautions: Animal Data In rats, oral doses of either [0m[1;31m533[0m[31m mg/kg sulfamethoxazole or [0m[1;31m200[0m[31m mg/kg trimethoprim produced teratologic effects manifested mainly[0m
[31mas cleft palates. These doses are approximately [0m[1;31m5[0m[31m and [0m[1;31m6[0m[31m times the recommended human total daily dose on a body surface area basis. In two studies in rats, no teratology was observed when [0m[1;31m512[0m[31m mg/kg of [0m
[31msulfamethoxazole was used in combination with [0m[1;31m128[0m[31m mg/kg of trimethoprim. In some rabbit studies, an overall increase in fetal loss [0m[1;31m([0m[31mdead and resorbed conceptuses[0m[1;31m)[0m[31m was associated with doses of [0m
[31mtrimethoprim [0m[1;31m6[0m[31m times the human therapeutic dose based on body surface area. Nonteratogenic Effects See CONTRAINDICATIONS section. Nursing Mothers Levels of sulfamethoxazole and trimethoprim in breast [0m
[31mmilk are approximately [0m[1;31m2[0m[31mâ€“[0m[1;31m5[0m[31m% of the recommended daily dose for infants over [0m[1;31m2[0m[31m months of age. BACTRIM: precautions: Caution should be exercised when BACTRIM is administered to a nursing woman, [0m
[31mespecially when breastfeeding jaundiced, ill, stressed, or premature infants because of the potential risk of bilirubin displacement and kernicterus. Pediatric Use BACTRIM is contraindicated for [0m
[31minfants younger than [0m[1;31m2[0m[31m months of age [0m[1;31m([0m[31msee INDICATIONS AND USAGE and CONTRAINDICATIONS sections[0m[1;31m)[0m[31m. Geriatric Use Clinical studies of BACTRIM did not include sufficient numbers of subjects aged [0m[1;31m65[0m[31m and [0m
[31mover to determine whether they respond differently from younger subjects. There may be an increased risk of severe adverse reactions in elderly patients, particularly when complicating conditions [0m
[31mexist, e.g., impaired kidney and/or liver function, possible folate deficiency, or concomitant use of other drugs. BACTRIM: precautions: Severe skin reactions, generalized bone marrow suppression [0m[1;31m([0m[31msee[0m
[31mWARNINGS and ADVERSE REACTIONS sections[0m[1;31m)[0m[31m, a specific decrease in platelets [0m[1;31m([0m[31mwith or without purpura[0m[1;31m)[0m[31m, and hyperkalemia are the most frequently reported severe adverse reactions in elderly patients. In[0m
[31mthose concurrently receiving certain diuretics, primarily thiazides, an increased incidence of thrombocytopenia with purpura has been reported. Increased digoxin blood levels can occur with [0m
[31mconcomitant BACTRIM therapy, especially in elderly patients. Serum digoxin levels should be monitored. Hematological changes indicative of folic acid deficiency may occur in elderly patients. These [0m
[31meffects are reversible by folinic acid therapy. Appropriate dosage adjustments should be made for patients with impaired kidney function and duration of use should be as short as possible to minimize [0m
[31mrisks of undesired reactions [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION section[0m[1;31m)[0m[31m. BACTRIM: precautions: The trimethoprim component of BACTRIM may cause hyperkalemia when administered to patients with underlying [0m
[31mdisorders of potassium metabolism, with renal insufficiency or when given concomitantly with drugs known to induce hyperkalemia, such as angiotensin converting enzyme inhibitors. Close monitoring of [0m
[31mserum potassium is warranted in these patients. Discontinuation of BACTRIM treatment is recommended to help lower potassium serum levels. Bactrim Tablets contain [0m[1;31m1.8[0m[31m mg sodium [0m[1;31m([0m[1;31m0.08[0m[31m mEq[0m[1;31m)[0m[31m of sodium per[0m
[31mtablet. Bactrim DS Tablets contain [0m[1;31m3.6[0m[31m mg [0m[1;31m([0m[1;31m0.16[0m[31m mEq[0m[1;31m)[0m[31m of sodium per tablet. Pharmacokinetics parameters for sulfamethoxazole were similar for geriatric subjects and younger adult subjects.         [0m
[31mSOUR[0m[1;31mCE:BAC[0m[31mTRIM label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: The BACTRIM label does not explicitly state whether BACTRIM increases or decreases the risk of hospitalization. However, it does mention that there may be an increased risk of severe adverse [0m
[32mreactions in elderly patients, particularly when complicating conditions exist, such as impaired kidney and/or liver function, possible folate deficiency, or concomitant use of other drugs. Severe [0m
[32madverse reactions could potentially lead to hospitalization. Additionally, AIDS patients may not tolerate or respond to BACTRIM in the same manner as non-AIDS patients, with an increased incidence of [0m
[32madverse reactions reported. Close monitoring and appropriate dosage adjustments are recommended for patients with increased risks.[0m

[32mSOURCE: BACTRIM label[0m
[32mEXTRACT_START_END: Geriatric Use Clinical studies[0m[32m...[0m[32m as short as possible to minimize risks[0m[32m...[0m
*[1m([0morchestrator-hospitalization-BACTRIM[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: The BACTRIM label does not explicitly state whether BACTRIM [0m
[34mincreases or decreases the risk of hospitalization. However, it does mention that there may be an increased risk of severe adverse reactions in elderly patients, particularly when complicating [0m
[34mconditions exist, such as impaired kidney and/or liver function, possible folate deficiency, or concomitant use of other drugs. Severe adverse reactions could potentially lead to hospitalization. [0m
[34mAdditionally, AIDS patients may not tolerate or respond to BACTRIM in the same manner as non-AIDS patients, with an increased incidence of adverse reactions reported. Close monitoring and appropriate [0m
[34mdosage adjustments are recommended for patients with increased risks.[0m

[34mSOURCE: BACTRIM label[0m
[34mEXTRACT_START_END: Geriatric Use Clinical studies[0m[34m...[0m[34m as short as possible to minimize risks[0m[34m...[0m
 [1m([0morchestrator-hospitalization-BACTRIM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-BACTRIM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-hospitalization-BACTRIM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does BACTRIM increase or decrease the risk of hospitalization?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether BACTRIM increases or decreases the risk of hospitalization."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the BACTRIM label does not explicitly state whether BACTRIM increases or decreases the risk of hospitalization."[0m[32m,[0m
[32m      [0m[32m"The label does mention that there may be an increased risk of severe adverse reactions in elderly patients, particularly with complicating conditions such as impaired kidney and/or liver [0m
[32mfunction, possible folate deficiency, or concomitant use of other drugs, which could potentially lead to hospitalization."[0m[32m,[0m
[32m      [0m[32m"Additionally, AIDS patients may not tolerate or respond to BACTRIM in the same manner as non-AIDS patients, with an increased incidence of adverse reactions reported."[0m[32m,[0m
[32m      [0m[32m"Close monitoring and appropriate dosage adjustments are recommended for patients with increased risks."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"The BACTRIM label does not explicitly state whether BACTRIM increases or decreases the risk of hospitalization. However, it does mention potential increased risks of severe adverse [0m
[32mreactions in certain populations, such as elderly patients with complicating conditions and AIDS patients, which could potentially lead to hospitalization. Therefore, while a direct causal [0m
[32mrelationship between BACTRIM and hospitalization risk is not established, there are scenarios where the risk of hospitalization might be increased due to adverse reactions."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hospitalization-BACTRIM[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-hospitalization-BACTRIM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hospitalization-BACTRIM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-hospitalization-BACTRIM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does BACTRIM increase or decrease the risk of hospitalization?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether BACTRIM increases or decreases the risk of hospitalization."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the BACTRIM label does not explicitly state whether BACTRIM increases or decreases the risk of hospitalization."[0m[34m,[0m
[34m      [0m[34m"The label does mention that there may be an increased risk of severe adverse reactions in elderly patients, particularly with complicating conditions such as impaired kidney and/or liver [0m
[34mfunction, possible folate deficiency, or concomitant use of other drugs, which could potentially lead to hospitalization."[0m[34m,[0m
[34m      [0m[34m"Additionally, AIDS patients may not tolerate or respond to BACTRIM in the same manner as non-AIDS patients, with an increased incidence of adverse reactions reported."[0m[34m,[0m
[34m      [0m[34m"Close monitoring and appropriate dosage adjustments are recommended for patients with increased risks."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"The BACTRIM label does not explicitly state whether BACTRIM increases or decreases the risk of hospitalization. However, it does mention potential increased risks of severe adverse [0m
[34mreactions in certain populations, such as elderly patients with complicating conditions and AIDS patients, which could potentially lead to hospitalization. Therefore, while a direct causal [0m
[34mrelationship between BACTRIM and hospitalization risk is not established, there are scenarios where the risk of hospitalization might be increased due to adverse reactions."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does BACTRIM increase or decrease the risk of hospitalization?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether BACTRIM increases or decreases the risk of hospitalization.[0m
[1;31m2[0m[31m. FDAHandler responded that the BACTRIM label does not explicitly state whether BACTRIM increases or decreases the risk of hospitalization.[0m
[1;31m3[0m[31m. The label does mention that there may be an increased risk of severe adverse reactions in elderly patients, particularly with complicating conditions such as impaired kidney and/or liver function, [0m
[31mpossible folate deficiency, or concomitant use of other drugs, which could potentially lead to hospitalization.[0m
[1;31m4[0m[31m. Additionally, AIDS patients may not tolerate or respond to BACTRIM in the same manner as non-AIDS patients, with an increased incidence of adverse reactions reported.[0m
[1;31m5[0m[31m. Close monitoring and appropriate dosage adjustments are recommended for patients with increased risks.[0m
[31m        -----[0m
[31m        Final answer: The BACTRIM label does not explicitly state whether BACTRIM increases or decreases the risk of hospitalization. However, it does mention potential increased risks of severe [0m
[31madverse reactions in certain populations, such as elderly patients with complicating conditions and AIDS patients, which could potentially lead to hospitalization. Therefore, while a direct causal [0m
[31mrelationship between BACTRIM and hospitalization risk is not established, there are scenarios where the risk of hospitalization might be increased due to adverse reactions.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-hospitalization-BACTRIM[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-hospitalization-BACTRIM[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-hospitalization-BACTRIM[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-hospitalization-BACTRIM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-hospitalization-BACTRIM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe final answer to the question [0m[32m"Does BACTRIM increase or decrease the risk of hospitalization?"[0m[32m is that the BACTRIM label does not explicitly state whether BACTRIM increases or decreases the risk of[0m
[32mhospitalization. However, the label does mention that there may be an increased risk of severe adverse reactions in elderly patients, particularly with complicating conditions such as impaired kidney [0m
[32mand/or liver function, possible folate deficiency, or concomitant use of other drugs, which could potentially lead to hospitalization. Additionally, AIDS patients may not tolerate or respond to [0m
[32mBACTRIM in the same manner as non-AIDS patients, with an increased incidence of adverse reactions reported. Close monitoring and appropriate dosage adjustments are recommended for patients with [0m
[32mincreased risks. Therefore, while a direct causal relationship between BACTRIM and hospitalization risk is not established, there are scenarios where the risk of hospitalization might be increased due[0m
[32mto adverse reactions.[0m
